Kaewput et al., 2022 - Google Patents
Update of PSMA theranostics in prostate cancer: current applications and future trendsKaewput et al., 2022
View HTML- Document ID
- 893134296145647570
- Author
- Kaewput C
- Vinjamuri S
- Publication year
- Publication venue
- Journal of Clinical Medicine
External Links
Snippet
There is now an increasing trend for targeting cancers to go beyond early diagnosis and actually improve Progression-Free Survival and Overall Survival. Identifying patients who might benefit from a particular targeted treatment is the main focus for Precision Medicine …
- 102100008453 FOLH1 0 title abstract description 148
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lenzo et al. | Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer | |
| Hennrich et al. | [68Ga] Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer | |
| Ruigrok et al. | The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research | |
| Vahidfar et al. | Theranostic advances in breast cancer in nuclear medicine | |
| Maurer et al. | Current use of PSMA–PET in prostate cancer management | |
| Rowe et al. | Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications | |
| Combes et al. | PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer | |
| Kaewput et al. | Update of PSMA theranostics in prostate cancer: current applications and future trends | |
| Czarniecki et al. | Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents | |
| Van de Wiele et al. | PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: a systematic review | |
| Lindenberg et al. | Imaging locally advanced, recurrent, and metastatic prostate cancer: a review | |
| Rosar et al. | Efficacy and safety of [225Ac] Ac-PSMA-617 augmented [177Lu] Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis | |
| Luining et al. | Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer | |
| Lindner et al. | Radioligands targeting fibroblast activation protein (FAP) | |
| Hofman et al. | Advances in urologic imaging: prostate-specific membrane antigen ligand PET imaging | |
| Plichta et al. | Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer | |
| Bartolazzi et al. | Galectin-3: the impact on the clinical management of patients with thyroid nodules and future perspectives | |
| Mokoala et al. | PSMA theranostics: science and practice | |
| Langbein et al. | Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225Ac-and 177Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation | |
| Khreish et al. | Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy | |
| Khalid et al. | Radiolabelled aptamers for theranostic treatment of cancer | |
| Hyväkkä et al. | More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and beyond | |
| Chernov et al. | Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors | |
| Ambrosini et al. | Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors | |
| Li et al. | The performance of FDA-approved PET imaging agents in the detection of prostate cancer |